

(12) PATENT APPLICATION PUBLICATION

(21) Application No.202331049754 A

(19) INDIA

(22) Date of filing of Application :24/07/2023

(43) Publication Date : 13/10/2023

(54) Title of the invention : NICKEL THIOSEMICARBAZONE COMPLEXES AS NOVEL ANTICANCER DRUG TOWARDS HUMAN BREAST CARCINOMA CELL LINE

(51) International classification :A61P0035000000, C07K0016300000, C07D0213380000, A61K0031175000, C07D0333200000
(86) International Application No :NA
Filing Date :NA
(87) International Publication No : NA
(61) Patent of Addition to Application Number :NA
Filing Date :NA
(62) Divisional to Application Number :NA
Filing Date :NA

(71)Name of Applicant :

1)Brainware University, Kolkata

Address of Applicant :398, Ramkrishnapur Rd, Near Jagadighata Market, Barasat, Kolkata, West Bengal 700125 -----

Name of Applicant : NA

Address of Applicant : NA

(72)Name of Inventor :

1)Dr. Sayanti Datta

Address of Applicant :Assistant Professor, Department of Chemistry, Brainware University, 398, Ramkrishnapur Rd, near Jagadighata Market, Barasat, Kolkata 700125 -----

2)Dr. Deepshikha Datta

Address of Applicant :Associate Professor, Department of Chemistry, Brainware University, 398, Ramkrishnapur Rd, near Jagadighata Market, Barasat, Kolkata 700125 -----

3)Mr. Mithun Maity

Address of Applicant :Assistant Professor, Department of Physics, Brainware University, 398, Ramkrishnapur Rd, near Jagadighata Market, Barasat, Kolkata 700125 -----

4)Dr. Vertika Rai

Address of Applicant :Assistant Professor, Department of Allied Health Sciences, Brainware University, 398, Ramkrishnapur Rd, near Jagadighata Market, Barasat, Kolkata 700125 -----

5)Ms. Suchismita Mukherjee

Address of Applicant :Assistant Professor, Department of Allied Health Sciences, Brainware University, 398, Ramkrishnapur Rd, near Jagadighata Market, Barasat, Kolkata 700125 -----

(57) Abstract :

The present invention discloses Nickel thiosemicarbazone complexes as novel anticancer drug towards human breast carcinoma cell line. The present invention proposes a method for synthesizing mononuclear nickel thiosemicarbazone complexes [Ni(L)(py)]. These complexes are derived by reacting various thiosemicarbazones with Ni(ClO₄)₂•6H₂O and pyridine as a co-ligand. The synthesized complexes retain their ligands in a unique ONS-fashion along with a nitrogen-coordinated pyridine, forming a slightly distorted square planar geometry. Notably, the pyridine remains trans to the central imine nitrogen, facilitating a distinct ONSN ligand environment around the nickel center. This particular environment is associated with significant cytotoxic behavior, a property further enhanced due to the presence of sulfur in the thiosemicarbazone complexes and the coordination with an N-donor ligand, pyridine. Of the complexes synthesized, [Ni(L₃)(py)] exhibits the highest efficiency as an anticancer drug, displaying a promising LD₅₀ value of 7.6 μM compared to conventional drugs. The patent hence offers potential in developing novel anti-cancer drugs.

No. of Pages : 15 No. of Claims : 9